ADVA
12.8.2021 09:02:11 CEST | Business Wire | Press release
ADVA (FSE: ADV) today introduced its FSP 150-XJ128 , the industry’s first Layer 2 demarcation device that offers an easy route to 25Gbit/s connectivity services. The solution is specifically designed to enable enterprise networks to expand in an easy and cost-effective way. Until now, businesses had to choose between juggling their 10Gbit/s devices or making the expensive leap to 100Gbit/s. With the ADVA FSP 150-XJ128, they can address soaring data demand without using complex modulation techniques or undergoing a costly footprint increase. The solution simply slots into existing network infrastructure and delivers 2.5x the bandwidth at a lower cost per bit.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210812005050/en/
“Our FSP 150-XJ128 is the technology that businesses have been calling for. It empowers them to take the natural next step with zero hassle and without unnecessary expense. For many enterprises, trying to manage rapidly rising bandwidth needs using 10Gbit/s demarcation devices has become a real headache. Yet it doesn’t make economic sense to overhaul their entire system and go all the way to 100Gbit/s. What we’re providing is the ideal stepping stone for secure business growth,” said Christoph Glingener, CTO, ADVA. “Until today, there was no middle ground. Now, businesses can slot our FSP 150-XJ128 into their existing network infrastructure and seize new revenue opportunities.”
The ADVA FSP 150-XJ128 is ideal for 5G sites moving to 25Gbit/s and the perfect choice for preparing cable networks for DOCSIS 4.0 and above. The compact device supports 25Gbit/s Ethernet services with sophisticated OAM capabilities. Optimized for cost-sensitive high-bandwidth edge applications, the ADVA FSP 150-XJ128 features fanless operation and an extended temperature range, removing the need for expensive air-conditioning. With its hardware-assisted synchronization features, it also meets the most stringent timing requirements. Managed by ADVA’s Ensemble Controller and Ensemble Packet Director , the FSP 150-XJ128 gives operations teams the power of intuitive and comprehensive network control.
“What we’re offering businesses is a solution that hits the sweet spot. It enables enterprise networks to handle significantly more workloads and data-hungry applications without major investment or increased complexity. Now there’s a way to meet the bandwidth needs of 5G and cloud computing without complex modulation techniques or breaking the bank,” commented Eli Angel, VP, product line management, ADVA. “As we’ve shown in several customer demos, our simple plug-and-play FSP 150-XJ128 delivers 2.5x the bandwidth in an instant. What’s more, it provides the Layer 2 demarcation and synchronization capabilities that enterprise networks require. Today’s launch marks the start of a new era of 25Gbit/s connectivity and a whole new world of opportunity for businesses.”
Further information on the ADVA FSP 150-XJ128 is available in these slides: https://adva.li/fsp-150-xj128-slides .
Additional details can also be found in this video: https://youtu.be/ikE9quU0gjc .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005050/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
